Tamoxifen has found many uses in medicine and science today, PCT, Gyno (bitch tit) and male infertility.
Currently, the only FDA approved use in breast cancer for men and women.
Tamoxifen blocks estrogen
Tamoxifen is metabolized into compounds that bind to the estrogen receptor but do not activate it.
When it comes to gynecomastia in men, it is generally assumed that there is a ratio of androgen and estrogen levels that cause this condition.
Aromatase inhibition has been tested as a possible therapy for gynecomastia. However, a 6-month study using 1mg of anastrozole daily for 180 days did not result in noteworthy results vs. placebo in boys.
In the end, tamoxifen has proven much more effective when it comes to the prevention of gyno.
It is now suggested that clinicians no longer recommend aromatase inhibitors (AI) as a first-line option in gynecomastia prevention.
As the use of testosterone replacement therapy is soaring high, as is the use of androgenic steroids in younger populations.
This is of grave concern for those who want to remain fertile as their use impairs the hypothalamus-pituitary-gonadal (HPG) axis.
It does not matter if the subject is Post cycle therapy or fertility; several prescribed arrangements may be used.
Tamoxifen is definitely in the mix as it allows healthy estrogen levels to survive yet binds to estrogen sites in the pituitary.
The effect is that tamoxifen use results in the elevated levels of luteinizing hormone and restoration of the hpa.
Tamoxifen is a certified Reference Material is for research use only